Pulmonary Thromboembolism in COVID-19

Kateryna Yevdokimova, Hooman D. Poor

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

Abstract

Coronavirus disease 2019 (COVID-19), the disease responsible for the devastating pandemic that began at the end of 2019, has been associated with a significantly increased risk of pulmonary thrombosis, even in patients receiving prophylactic anticoagulation. The presence of pulmonary thrombosis may explain why hypoxemia is out of proportion to impairment in lung compliance in some patients with COVID-19 pneumonia. Because pulmonary embolism and COVID-19 pneumonia share many signs and symptoms, diagnosing pulmonary embolism in patients with COVID-19 can be challenging. Given the high mortality and morbidity associated with severe COVID-19, and the concern that aspects of the disease may be driven by thrombosis, many hospital systems have instituted aggressive anticoagulation protocols above standard venous thromboembolism prophylaxis. In this review, the epidemiology, pathophysiology, diagnosis, and treatment of PE in COVID-19 are discussed.

Original languageEnglish
Title of host publicationPulmonary Embolism
PublisherSpringer International Publishing
Pages249-258
Number of pages10
ISBN (Electronic)9783030870904
ISBN (Print)9783030870898
DOIs
StatePublished - 1 Jan 2021

Keywords

  • Anticoagulation
  • COVID-19
  • Immunothrombosis
  • Pulmonary embolism
  • Thrombosis

Fingerprint

Dive into the research topics of 'Pulmonary Thromboembolism in COVID-19'. Together they form a unique fingerprint.

Cite this